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ABSTRACT
Array-based comparative genomic hybridization is
a high resolution method for measuring chromo-
somal copy number changes. Here we present a
validated protocol using in-house spotted oligonuc-
leotide libraries for array comparative genomic
hybridization (CGH). This oligo array CGH platform
yields reproducible resultsand iscapable ofdetecting
single copy gains, multi-copy amplifications as well
as homozygous and heterozygous deletions as small
as 100 kb with high resolution. A human oligonuc-
leotide library was printed on amine binding slides.
Arrays were hybridized using a hybstation and
analysed using BlueFuse feature extraction software,
with .95% of spots passing quality control. The
protocol allows as little as 300 ng of input DNA and
a 90% reduction of Cot-1 DNA without compromising
quality. High quality results have also been obtained
with DNA from archival tissue. Finally, in addition
to human oligo arrays, we have applied the protocol
successfully to mouse oligo arrays. We believe that
this oligo-based platform using ‘off-the-shelf’ oligo
libraries provides an easy accessible alternative to
BAC arrays for CGH, which is cost-effective, avail-
able at high resolution and easily implemented for
any sequenced organism without compromising the
quality of the results.
INTRODUCTION
Microarray comparative genomic hybridization (CGH) is now
the method of choice for the detection of DNA copy number
changes, such as gains, losses, amplifications and (micro-)
deletions in tumours and genetic diseases (1,2). The first whole
genome microarray contained 2400 large-insert genomic
clones, primarily bacterial artificial chromosomes (BACs)
(3). With the total human genome covering 3000 Mb, the
resolution of this array is on average close to 1 Mb, about one
order of magnitude higher than that obtained with classical
CGH (4). For a full coverage resolution array 30 000 BACs
have been arrayed (5), increasing the resolution with another
order of magnitude. However, producing such large numbers
of BACs for array CGH is expensive and time-consuming and
due to the large size of the BACs, the limits of BAC array CGH
resolution have been reached. These problems can be over-
come when oligonucleotides are used as targets in microarray
experiments. Oligonucleotides allow a sheer infinite resolu-
tion, great flexibility and are cost-effective (6). Moreover,
oligonucleotides allow for the generation of microarrays for
any organism of which the genome has been sequenced.
Attempts have been undertaken to increase the resolution of
BAC arrays in other ways, such as BAC-based (7) or exon-
based (8) PCR-fragments, but both are laborious ways to
generate targets for whole genome array CGH that cannot
compete with the flexibility and versatility of oligonucleotides.
Finally, oligonucleotide arrays are being used, designed and
accepted for expression profiling and thus widely available.
Using the same oligo array for CGH and expression profiling
allows direct comparison of mRNA expression and DNA copy
number ratios (9).
We have published results showing proof of principle for
the use of spotted 60mer oligonucleotides for high resolution
microarray CGH (6). Commercially available oligonucleotide
microarray platforms have also successfully been used for
array CGH (10–12). The aim of the current study was to
optimize and validate our protocol for in-house spotted oligo
array CGH. We present results showing high resolution
detection of single copy gains, amplifications and (micro-)
deletions. Fluorescence in situ hybridization (FISH) has
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been used to validate both homozygous and heterozygous
deletions. The presented oligo array CGH protocol provides
a highly sensitive and reproducible platform both for human
and mouse samples applicable to DNA isolated from both
fresh and formalin fixed paraffin embedded (FFPE) tissue
as validated by BAC arrays. For laboratories that already
have oligonucleotide-based expression array platforms run-
ning or are planning to, we here provide protocols with
which those platforms can easily be adapted for array CGH.
MATERIALS AND METHODS
Oligo array preparations
The Human Release 2.0 oligonucleotide library, containing
60mer oligonucleotides representing 28 830 unique genes
and the Mouse Release 2.0 oligonucleotide library, containing
65mer oligonucleotides representing 21 587 unique genes as
designed by Compugen (San Jose, CA, USA), were obtained
from Sigma-Genosys (Zwijndrecht, The Netherlands). The
oligonucleotides were dissolved at 10 mM concentration in
50 mM sodium phosphate buffer pH 8.5 and single spotted
onto CodeLink slides (Amersham Biosciences), using an
OmniGrid 100 microarrayer (Genomic Solutions,
Ann Arbor, MI, USA) equipped with SMP3 pins (TeleChem
International, Sunnyvale, CA, USA). After printing slides
were processed and blocked prior to use according to the
manufacturer’s protocol.
DNA isolation and labelling
Genomic DNA was isolated from blood obtained from
10 males or 10 females using DNAzol (Invitrogen) according
to the manufacturer’s protocol and was pooled for use as
reference DNA. Genomic DNA from cell lines BT474
(ATCC nr. HTB-20), MDA-MB-468 (ATCC nr. HTB-132),
SKBR7 (obtained from Dr M. J. O’Hare, Ludwig Institute for
Cancer Research, London, UK), SUM159, GM01750,
GM13031 and GM07408 (obtained from Coriell Institute
for Medical Research, Camden, USA) was isolated according
to Snijders et al. (3). Genomic DNA from FFPE gastric tumour
was isolated according to Weiss et al. (13).
DNA labelling was performed essentially according to
Snijders et al. (3) using the BioPrime DNA labelling system
(Invitrogen). Genomic DNA (300 ng) was mixed with 20 ml of
2.5· Random primer (Invitrogen) and MilliQ water to a total
volume of 42 ml. The mixture was then incubated for 10 min
at 100C to denature the DNA, instantly cooled down on
ice/water and kept on ice while adding 5 ml of dNTP mixture
(2 mM dATP, 0.5 mM dCTP, 2 mM dGTP, 2 mM dTTP, 10
mM Tris pH 7.6, 1 mM EDTA) 2 ml of 1 mM Cy3-dCTP (test
sample) or Cy5-dCTP (pooled reference sample) (Perkin
Elmer) and 1 ml of Klenow DNA polymerase (40 U/ml, Invit-
rogen). After gently mixing the DNA was incubated for 16 h at
37C. Unincorporated label was removed before mixing test
and reference samples using ProbeQuant G-50 Micro Columns
(Amersham Biosciences) according to the manufacturer’s pro-
tocol, by applying the sample to the top centre of the resin
while being careful not to disturb the resin bed. The purified
sample was stored in the dark until used on the same day or at
20C for longer storage.
Hybridization
For preparation of the hybridization mixture of both human
and mouse samples 50 ml of Cy3-labelled test DNA, 50 ml of
Cy5-labelled reference DNA and 10 mg Human Cot-1 DNA
(Invitrogen) were mixed and precipitated using 0.1 vol of 3 M
NaAc pH 5.2 and 2.5 vol of ice-cold absolute ethanol. After
mixing by inversion the DNA was collected by centrifugation
for 30 min at 20 000 g and 4C, the supernatant aspirated
and the pellet air-dried for 5–10 min. The pellet was then
dissolved in 13 ml Yeast tRNA (100 mg/ml, Invitrogen) and
26 ml 20% SDS taking care to prevent foam formation. After
incubating at room temperature for 15 min 91 ml of Master
mix [14.3% (w/v) dextran sulphate (USB), 50% (v/v) form-
amide (Invitrogen), 2.9· SSC pH 7.0 (Sigma)] was added and
gently mixed. The hybridization solution was then incubated at
73C for 10 min to denature the DNA and subsequently at
37C for 60 min to allow the Cot-1 DNA to block repetitive
sequences. Hybridization and washing were done automatic-
ally using a GeneTAC/HybArray12 hybstation (Genomic
Solutions/Perkin Elmer). Hybridization was done for 38 h
at 37C. Subsequently slides were washed 6 cycles (flow
for 10 s, hold for 20 s) with 50% (v/v) formamide, 2· SSC,
2 cycles with phosphate-buffer [0.1 M Na2HPO4/NaH2PO4,
pH 8.0, 0.1% (v/v) Igepal CA630 (Sigma)], 2 cycles with
0.2· SSC (Sigma) and 2 cycles with 0.1· SSC. Slides were
then taken out of the hybstation and briefly rinsed in 0.01·
SSC, dried by centrifugation for 3 min at 1000 g and scanned
using an Microarray Scanner G2505B (Agilent Technologies).
Analysis
Spot analysis and quality control were fully automated using
BlueFuse version 3.1 (BlueGnome, Cambridge, UK). Spots
were excluded when the quality flag was <1 or the Confidence
value <0.1. Oligonucleotides from the human library were
mapped to the human genome build NCBI35 and from the
mouse library to the mouse genome build NCBIm33 (Ensembl
v31). Oligonucleotide sequences and mapping have been
made accessible by Compugen (San Jose, CA, USA) and The
Sanger Institute (Hinxton, Cambridge, UK), respectively, via
www.ensembl.org. A unique chromosomal position was iden-
tified for 26 845 of the 28 830 oligonucleotides in the human
library. For the mouse library, 15 140 oligonucleotides of the
21 587 had a unique position. Oligonucleotides were excluded
when they mapped to more than one position in the genome
or showed one or more mismatches with regard to the current
build.
Log2ratios of spots that were not excluded after quality
flagging and mapping were normalized to their mode value.
Weighted moving average values were then calculated using a
triangular function and a window of 250 kb as described (11)
solely to display genomic profiles where indicated. Break-
points, gains, losses and amplifications were detected using
the January 2005 version of ArrayCGHsmooth (14) that uses
a ratio-dependent penalty for breakpoints in order to facilitate
the detection of amplifications. Genetic Algorithm Parameters
used were lambda: 3, pool size: 300, maximum number
of breakpoints initial pool: 10 and maximum number of
generations: 5000. The minimum difference between levels
for the ‘Join Closest Levels’ parameter was 0.1. The ‘new ratio
join’ levels were used to display in the figures.
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Fluorescence in situ hybridization
FISH was performed using BAC clones identified for the
deleted region of interest i.e. the RB1 gene was identified
from Ensembl to be contained within the RP11-305D15
BAC clone while the deleted region of 12q24 is represented
by three BACs RP11-340F14, RP11-44F24 and RP11-7M8.
The BAC DNA was isolated by the alkaline-lysis method and
labelled with biotin-16-dUTP (Roche Biochemicals, UK)
using nick translation (Vysis, UK). The labelled BAC was
precipitated together with a whole chromosome 13 paint
labelled with Spectrum Orange (Abbott Diagnostics, UK) in
the presence of unlabelled Human Cot-1 DNA. The precipit-
ated DNA was resuspended in hybridization buffer (50%
formamide/10% dextran sulphate/2· SSC).
Metaphase preparations from MDA-MB-468 were obtained
using standard potassium chloride/Carnoy’s fixative protocols
and stored at 20C or from peripheral blood lymphocytes
of normal individuals for reference. Slides were denatured in
70% formamide/2· SSC at 72C for 1 min and immersed into
ice-cold ethanol series (70, 90 and 100%) for 3 min each. A
total of 15 ml of probes were denatured at 72C for 10 min,
allowed to pre-anneal at 37C for 30 min and applied onto
slides for a 72 h hybridization. Bound probes were detected
with streptavidin-FITC (Vector Labs, UK) and counterstained
with DAPI in a mounting medium (Vectashield, Vector Labs,
UK). Slides were examined under a Zeiss Axioplan 2 epifluor-
escence microscope equipped with single band pass emission
filters. Digital images were taken using a Hamamatsu ORCA II
camera (Hamamatsu, Japan) operated via the SmartCapture
Software (Digital Scientific, UK).
Human and mouse BAC arrays
As control experiments both human and mouse BAC arrays
have been used. BACs for the 5 K human array were collected
and amplified as described (6) and spotted in triplicate using
an OmniGrid 100 microarrayer (Genomic Solutions, Ann
Arbor, MI, USA) equipped with SMP3 pins (TeleChem
International, Sunnyvale, CA, USA). After printing slides
were processed and blocked prior to use according to the
manufacturer’s protocol, hybridized as described (6) and
scanned using a Microarray Scanner G2505B (Agilent Tech-
nologies). Results were analysed as described earlier for oligo
arrays with the addition that triplicates from the human BAC
arrays were fused by BlueFuse in a weighted fashion. The
human BAC clones were mapped to the human genome
build NCB134. Production, DNA isolation, DNA labelling,
hybridization, scanning and analysis of 1 Mb mouse BAC
arrays were done completely according to Chung et al.
(15). The lambda parameter setting for BAC in ArrayCGHs-
mooth (14) was set to 1.5.
RESULTS
Performance, sensitivity and reproducibility
We have optimized the quality of our in-house oligo array
CGH platform (6) using enhanced, automated hybridization
conditions and a newly designed extended oligonucleotide
library. In addition, we have used BlueFuse feature extraction
software enabling fully automated spot analysis. Using these
new measures two major goals were achieved owing to the
optimized protocol. First, a significant reduction in the amount
of background signal was obtained, resulting in a substantial
decrease in the number of flagged spots. Second, the variation
as defined by the SD in areas without detected copy number
changes was considerably reduced. Simultaneously, we have
cut the total hybridization costs by removing the prehy-
bridization and reducing the amount of Cot-1 DNA by 90%
without compromising quality.
The capability of the current oligo platform to detect and
map chromosomal aberrations is demonstrated by a hybrid-
ization of DNA from the breast tumour cell line BT474 with
normal male human reference DNA (Figure 1A). In another
experiment we hybridized DNA from an individual normal
female sample with DNA from a pool of normal male
samples (Figure 1B). The genome-wide profiles from these
experiments are displayed with a weighted moving average
of 250 kb to facilitate visual interpretation. The BT474
profile shows many well-defined gains, losses and ampli-
fications as calculated by the smoothing algorithm (14) and
the female–male profile shows a straight line with only the
X-chromosome gain and Y-chromosome loss, confirming
the sex mismatch. With 25 388 (BT474) or 25 030 (female–
male) uniquely mapped oligonucleotides that passed
quality control, from a total of 26 845 oligonucleotides,
>93% of spots were used for calculations resulting in a res-
olution of100 kb on average. Reproducibility of these results
is demonstrated by three additional technical repeats of the
BT474 and seven additional biological repeats of female–
male hybridizations. Statistics for these and all other
array experiments described are provided in Supplementary
Table 1.
Variation between consecutive oligonucleotides in an area
without chromosomal aberrations is an accumulative con-
sequence of technical noise and biological variation, which
is the copy number variations across individuals (16), in this
case BT474 and the pooled reference. Snijders et al. (3) make
the same distinction for BAC arrays. Technical noise here is
defined as the SD of a particular oligonucleotide across a series
of experiments, further referred to as intra-oligonucleotide
variation. Individual copy number variations cannot be meas-
ured independently, but are part of the inter-oligonucleotide
noise, defined as the SD within one array and chromosomal
area without copy number changes. To estimate the inter-
oligonucleotide variation in the BT474 profile we measured
the SD of the log2ratio on chromosome 2 where no chromo-
somal copy number changes are observed. This SD is 0.25
when calculated on the raw data and 0.13 when a weighted
moving average with a window of 250 kb is applied. By
comparison, the SD on the log2ratios in chromosome 2 in
the BT474 BAC profile from Snijders et al. (3) (hybridization
4001024) is 0.17. In order to visualize the actual variation and
resolution detailed views of chromosome 17 from both experi-
ments without moving average are shown in Figure 1C
(BT474) and D (female–male). The amplifications are well-
defined and the results suggests a fifth amplification at 17q24.1
(Figure 1C, arrow) that has not been observed in a 1 Mb BAC
array (3).
The performance of the current oligo array CGH platform as
defined by the capability to detect single copy number differ-
ences, was assessed by a hybridization of DNA from the male
cell line GM01750 with two validated single copy gains on
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chromosomes 9 and 14, respectively (3), and a pool of normal
female reference DNA. Median and SD of the log2ratio from
the chromosome 9 single copy gain (ratio ¼ 3/2) and double
copy X-chromosome variations (ratio ¼ 1/2) are displayed
against the theoretical ratios (Figure 2A). The correlation
coefficient is 0.98 and the slope is 0.38. Ideally, measured
ratios would be the same as theoretical ratios (slope is 1)
(1), but alike results with BAC arrays (1) this is not the
case. The overlap between the SDs (Figure 2A, blue error
bars) indicate that the result of a single oligonucleotide is
statistically non-informative to call a single copy number
change. If a moving average of 3 is applied to the data
(Figure 2A, red error bars), SDs no longer overlap. Thus,
three consecutive oligonucleotides are sufficient to call a sin-
gle copy number change. The single copy gain on chromo-
some 9 shown in Figure 2B indeed demonstrates that the
oligo array CGH platform is powerful for effective break-
point detection. Similar results were obtained with two
more validated cell lines, GM13031 and GM07408 (Supple-
mentary Table 1).
Variation due to intra-oligonucleotide noise was evaluated
by analysing four hybridizations using one batch of BT474
DNA with normal male human reference DNA. Hybridiza-
tions were done independently on four different days and on
three different print batches of the 29 K human oligo arrays. A
detailed view of part of chromosome 2 from all four hybrid-
izations shows the resemblance between the profiles from each
hybridization (Figure 3). The average of the SDs calculated
per oligo (technical noise) from the four experiments is
0.14, whereas for BAC arrays a value of 0.08 was obtained
(3). Thus, this experiment shows that variation between the
log2ratios obtained from different oligonucleotides within one
experiment is reproducible, as shown by the low technical
noise value (intra-oligonucleotide noise).
Detection of deletions
The most difficult events to show by array CGH are chro-
mosomal deletions (9). The signal in the test channel is
very low, thus can only be accurately measured if background
is minimal. Here we show that our current oligo array CGH
platform is able to detect both heterozygous and homozygous
deletions with high resolution. A potential homozygous dele-
tion was revealed on chromosome 13 in the breast cancer cell
line MDA-MB-468 (Figure 4A). The deletion spanned 100
kb from position 47 883 to 47 977 kb which falls within
13q14.2 encompassing retinoblastoma 1 (RB1) and was not
detected in another cell line, illustrated by SUM159
(Figure 4C). To verify the deletion, we applied FISH using
a probe for RB1 combined with chromosome 13 paint. We
Figure 1. Capability of the oligo array CGH platform to detect and map chromosomal aberrations. Genome-wide profiles are shown that were obtained from
hybridization of BT474 DNA (A) with human male reference DNA or (B) normal male with normal female DNA on a 29 K human oligonucleotide array. Log2ratios
were calculated with a weighted moving average as described (11) using a window of 250 kb and are displayed as a function of their position in the genome. Log2ratios
of the odd and even chromosomes are shown in aqua blue and black, respectively. Chromosome numbers are indicated. Smoothed values of the log2ratios were
calculated using a dedicated smoothing algorithm (14) (red). Note the many breakpoints, gains, losses and amplifications in the BT474 profile and the lack of those in
the male–female profile. Detailed profiles of chromosome 17 for the BT474 (C) and male–female (D) hybridizations. Log2ratios were calculated without moving
average and are displayed in black as a function of their position on chromosome 17. Smoothed values of the log2ratios (red). The arrow in C indicates a fifth
amplification in the BT474 profile on chromosome 17 that was not observed in a 1 Mb BAC array (3).
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found two copies of RB1 (green signals) in metaphases from
SUM159 (Figure 4D), but none in MDA-MB-468 (Figure 4B).
In addition, chromosome painting showed that there was one
normal chromosome 13 and two marker chromosomes with
chromosome 13 material. This confirms the homozygous dele-
tion detected by oligo array CGH.
Another potential deletion was detected on chromosome
12 in the hypo diploid breast cancer cell line SKBR7
(Figure 5A). The oligo ratios indicated a deleted region span-
ning 2 Mb. To verify the deletion we applied FISH using
3 BACs that were encompassed within the deleted region:
RP11-340F14, RP11-44F24 and RP11-7M8 (Figure 5B).
We found an interstitial deletion involving all three BACs
on one of the two copies of chromosome 12 in this cell
line, confirming the presence of a heterozygous deletion.
Thus, both homozygous and heterozygous (micro-) deletions
can be detected.
Performance using DNA from archival specimens
Experiments described above have been performed using high
quality DNA obtained from either cell lines or frozen tumour
tissue. DNA isolated from FFPE tumour samples is slightly
degraded and gives sub-optimal results on BAC array CGH
platforms (17). Since the use of FFPE material is invaluable
for cancer research, we tested if DNA obtained from FFPE
samples can also be used with oligo arrays, which to our
knowledge has not yet been reported. DNA obtained from
an FFPE gastric tumour was hybridized with normal human
reference DNA to a human oligo array and for comparison,
with a 1 Mb human BAC array. Figure 6 shows a detailed view
of the log2ratios obtained from either the oligo array
(Figure 6A) or the BAC array (Figure 6B) for chromosomes
19–21. The genome-wide profile of these as well as technical
replicates of these experiments are available via GEO series
accession GSE3264 and Supplementary Table 1 provides
statistics on the reproducibility. There is a remarkable simil-
arity in the profiles calculated by the smoothing algorithm
from the oligo and the BAC array. The amplification in chro-
mosome 19 is clearly detected as well as several levels of
deletions in chromosome 21. In addition using the oligo
array, the positive log2ratios for amplifications and the neg-
ative log2ratios for deletions were higher when compared with
the BAC results. Additional FFPE DNA samples as well as
lung tumour DNA samples of poor quality due to microdissec-
tion were compared using both the oligo and BAC array CGH
platforms, yielding matching results (data not shown). Thus,
the oligo array CGH platform can perform at least as well as a
1 Mb BAC array platform when it comes to detecting copy
number changes in FFPE samples.
Mouse oligo array CGH
The availability of a 1 Mb resolution mouse BAC library (15)
provided the opportunity to evaluate the performance of our
21 K mouse oligonucleotide library in array CGH. Genomic
DNA obtained from two different mouse tumours was labelled
and hybridized to mouse oligo arrays (single printed) and in
Figure 2. Performance of the oligo array CGH platform. (A) DNA from the cell
line GM01750 was hybridized against normal female reference DNA. Copy
number changes were detected using the smoothing algorithm (14). Blue:
median values and SDs (error bars) were calculated for the areas with different
copy numbers and are displayed as a function of the theoretical log2ratio.
The different areas were the X-chromosome (theoretical ratio ¼ 1/2,
log2ratio ¼ 1), chromosomes 1–8, 10–13 and 15–22 (theoretical
ratio ¼ 2/2, log2ratio ¼ 0) and the gain in chromosome 9 (theoretical
ratio ¼ 3/2, log2ratio ¼ 0.58). The correlation coefficient is 0.98 and the slope
is 0.38. Red: same values calculated after applying a moving average of 3 to the
data. Note that the red error bars do not overlap. (B) Detailed profile of chro-
mosome 9 of the GM01750 hybridization. Log2ratios were calculated without
moving average and are displayed in black as a function of their position on
chromosome 9. Smoothed values of the log2ratios (red).
Figure 3. Reproducibility of the oligo array CGH platform. BT474 DNA was
hybridized four times against normal human male reference DNA on four
different days and on three different batches of 29 K human oligo arrays.
Log2ratios were calculated without moving average and are displayed in
different colours as indicated for each experiment as a function of their position
on chromosome 2.
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fluor-reversed experiments to the mouse BAC arrays (printed
in duplicate) (GEO accession GSE3264). Genomic profiles
obtained from one of these tumours are shown (Figure 7).
All profiles show a striking degree of similarity, despite dif-
ferences in noise and number of probes. For instance, in
Figure 7 chromosome 1 shows two distinct deletions in both
profiles and the amplifications as well as the deletion on chro-
mosome 10 completely match. In some cases the smoothed
pattern is not exactly the same in both profiles (i.e. chromo-
some 7), but usually is more refined in the oligo profile, most
likely due to the larger number of data points. As observed for
the human oligo and BAC arrays in Figure 6 also the positive
log2ratios for amplifications and the negative log2ratios for
deletions were higher for the mouse oligo arrays compared
with the mouse BAC array results. These data show that the
oligo array CGH protocol can successfully be applied to
mouse oligo libraries in order to assess copy number changes
in mouse samples.
DISCUSSION
In this paper we show that the current, optimized protocol for
oligo array CGH results in high resolution, reproducible data
providing a high quality, cost-effective platform for the detec-
tion of chromosomal aberrations in samples from various
sources. As our results show, the oligo array CGH platform
can detect amplifications (Figure 1), deletions as small as
100 kb (Figure 4), as well as single copy gains (Figure 2)
and losses (Figure 5) in single hybridization experiments.
When compared with results obtained with a 1 Mb BAC
array, the resolution is at least as good and at times
Figure 4. Detection of a homozygous deletion by the oligo array CGH platform. DNA from the cell lines MDA-MB-468 (A) and SUM159 (C) was hybridized with
normal male reference DNA on a human oligo array. Log2ratios were calculated without moving average and are displayed in black as a function of their position on
chromosome 13. The smoothed values of the log2ratios are displayed in red and the position of the RB1 oligo is indicated by the green circle in A and the arrow in C.
Note the lack of the deletion in SUM159. Validation of the HD by FISH analysis in cell lines: MDA-MB-468 (B) and SUM159 (D). The green signal from the RB1
probe clearly shows the presence of RB1 in SUM159 (D), but is absent from MDA-MB-468 (B). Chromosome 13 paint (red) shows the presence of three normal
copies of chromosome 13 and two marker chromosomes with chromosome 13 material.
Figure 5. Detection of a heterozygous deletion by the oligo array CGH plat-
form. (A) DNA from the cell line SKBR7 was hybridized with normal male
reference DNA on a human oligo array. Log2ratios were calculated without
moving average and are displayed in black as a function of their position on
chromosome 12. The smoothed values of the log2ratios are displayed in red. (B)
Validation of the heterozygous deletion on 12q24 by FISH analysis of cell line
SKBR7. Chromosome 12 paint (dark blue) shows two copies of seemingly
normal chromosome 12. FISH using 3 BACs, RP11-340F14 (red), RP11-44F24
(green) and RP11-7M8 (aqua blue) confirmed the interstitial deletion on one
copy of chromosome 12 (arrow). Overlapping FISH signals from different
BACs show up in white.
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considerably better, providing a more refined genomic profile.
Furthermore, we demonstrate that good quality results can be
obtained with this platform using archival DNA. Finally,
labelling DNA from a mouse tumour sample and hybridizing
it to the mouse oligo array (Figure 7) showed how easy it was
to apply the oligo array CGH platform to a new species.
Optimized hybridization conditions resulted in better
signal-to-background ratios. As a result, when using a good
quality DNA sample, <5% of spots would not pass quality
control, much less than the 65% we previously reported (6). In
addition, the inter-oligonucleotide noise as defined by the SD
in an area without chromosomal aberrations has been consid-
erably decreased from 0.45 previously (6) to 0.25 with the
current protocol (see also Supplementary Figure 1 allowing a
direct comparison of the optimized protocol with the previous
one). On average from all fresh human DNA samples analysed
in this study using the present protocol, the -oligonucleotide
noise is even as low as 0.22 (±0.03) with 91% (±5%) of spots
passing quality control (data extracted from Supplementary
Table 1). Moreover, we show that the technical noise (intra-
oligonucleotide variation) is as low as 0.14. Finally, only
300 ng of input DNA is needed for efficient labelling, almost
one order of magnitude less than that needed in other protocols
(11,18), omitting the need for amplification for many samples.
Breakpoints and copy number changes are easily detected
using a dedicated smoothing algorithm (14), although the per-
formance of the oligo array platform, as defined by the relation
between the measured and theoretical ratio (11), may not be
the most optimal (Figure 2). The platform is also sensitive
enough to detect single copy gains (Figure 2) as well as
heterozygous deletions (Figure 5). It is likely that homozygous
and heterozygous deletions can be distinguished from each
other if such difference appears within one experiment. Our
results do show evidence that the performance of oligo arrays
is comparable with those of BAC arrays (Figures 6 and 7). The
suppressed performance of measured versus theoretical ratios
is also observed using BAC arrays and is thought to result
from incomplete suppression of repetitive sequences (3). This
explanation would not be applicable to oligonucleotides,
because they are designed within unique genomic sequences.
We have successfully tried to take advantage of the lack
of repetitive sequences in the oligonucleotide library by
Figure 6. Validation of the oligo array CGH platform with DNA obtained from
FFPE tissue. DNA from an FFPE gastric tumour was hybridized with normal
human reference DNA on a human oligo array (A) and a 1 Mb human BAC array
(B). Log2ratios were calculated without moving average and are displayed for
chromosomes 19–21 as a function of their position on the genome. Log2ratios
of the odd and even chromosomes are shown in aqua blue and black,
respectively. Chromosome numbers are indicated. Smoothed values of the
log2ratios (red).
Figure 7. Validation of the mouse oligo array CGH platform. DNA from a
mouse tumour was hybridized with normal mouse reference DNA on a 21 K
mouse oligo array (A). Log2ratios were calculated with a weighted moving
average as described (11) using a window of 250 kb and are displayed as a
function of their position in the genome. The same mouse tumour and reference
DNA was hybridized in a paired fluor-reversed experiment (dye-swap) to a
1 Mb mouse BAC array (B). Log2ratios were calculated as described (15) and
displayed as a function of their position in the genome. Log2ratios of the odd
and even chromosomes are shown in aqua blue and black, respectively.
Smoothed values of the log2ratios (red).
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experimenting with lower Cot-1 DNA concentrations during
hybridization. Removing 90% of the amount of Cot-1 DNA
used for hybridization of BAC arrays did not have any effect
on the results (Supplementary Figure 2). Removing all Cot-1
DNA is possible as most aberrations were detected, but
showed a suppressing effect on the ratios, especially those
in deletions (Supplementary Figure 2). Although theoretically
there is no reason for the use of Cot-1 DNA, apparently the
presence of small amounts of Cot-1 DNA is yet advantageous
in our hands. Interestingly, the use of Human Cot-1 DNA for
the mouse oligo array hybridization produced good results.
When evaluating the reproducibility of the oligo array CGH
platform, we noticed that the technical noise of an individual
oligonucleotide in independent repeats (intra-oligonucleotide
variation), is considerably lower than the variation between
consecutive oligonucleotides within one experiment (inter-
oligonucleotide variation). A considerable difference between
technical noise and variation amongst consecutive clones has
also been demonstrated for BAC arrays (3), which is a con-
sequence of small chromosomal copy number variations
between individuals (16,19). Despite the selection of unique
oligonucleotides some cross-hybridization may still occur.
However, while array CGH-specific design of oligonuc-
leotides, aimed to minimize cross-hybridization, may improve
the performance of an oligo array CGH platform, it does not
decrease the variation when compared with oligonucleotides
designed for expression arrays (11).
When compared with BAC arrays, signal intensities
obtained in oligo arrays are relatively low, explaining part
of the noise (SD) observed in profiles from oligo arrays.
This is however compensated for by the high number of oli-
gonucleotides when compared with the number of BACs in a
1 Mb BAC array. Moreover, in both human and mouse array
experiments ratios obtained by the BAC arrays were slightly
compressed compared with the corresponding oligo arrays
(Figures 6 and 7). The profiles calculated by the smoothing
algorithm (14) are usually very similar between oligo and
BAC array experiments from the same sample. In areas
where the difference in probe density is high and many aber-
rations occur the smoothing algorithm may result in different
profiles. The high number of oligonucleotides then tends to
indicate a more refined pattern of aberrations. A moving aver-
age is used to illustrate the sensitivity of an individual element
on the oligonucleotide CGH arrays. This shows that three
oligonucleotides are sufficient to call for a single copy change.
In reality the resolution for downstream analysis of the arrays
is higher due to the implementation of sophisticated seg-
mentation algorithms such as ArrayCGHsmooth used here
(14,20,21). The average spacing between the oligonucleotides
in the human library is100 kb, but one should realize that the
actual spacing can be very much different. Because most oligo
libraries have so far been designed for expression arrays, oligo
array CGH will mainly focus on gene-rich areas. Also gene-
rich chromosomes, such as chromosome 19, will have a lower
average spacing (35 kb) than gene-poor chromosomes, such as
chromosome 4 or the X-chromosome (170 kb). Although
oligonucleotides are not evenly spread along the genome, in
75% of all oligonucleotides in the human library the distance
to the next oligo is <100 kb. Thus, theoretically, the resolution
is almost one order of magnitude higher than that of a 1 Mb
BAC array for most of the genome.
We have done several hundreds of oligo array CGH exp-
eriments in our lab and usually obtain clear profiles. Over 150
of these were breast tumour samples and have confirmed res-
ults obtained using Vysis BAC arrays (data not shown). We
thus strongly believe that this oligo array CGH protocol pro-
vides a robust and reproducible platform. We further evaluated
whether our optimized protocol could be replicated in inde-
pendent laboratories. DNA from the cell line MCF7 was
labelled and hybridized to a human oligo array both in our
laboratory and by an experienced array CGH group (O. Monni,
personal communication) according to the current protocol
and very similar results were obtained (not shown). In another
experiment DNA from a lung tumour sample was hybridized
to the 29 K human oligo array that was printed both on a
CodeLink as well as a home-made poly-L-lysine coated
slide by a group experienced in oligo arrays (L. Miller,
personal communication) resulting in high quality data (Sup-
plementary Figure 3) for both slide types. Although the ratios
obtained from the poly-L-lysine slide were compressed when
compared with those from the CodeLink slide and the noise
was lower on the CodeLink slide, indicating that slide chem-
istry may be an important factor that contributes to the quality
of the data, essentially the same aberrations were detected on
both slide types.
Although tiling resolution BAC arrays have been developed
(5) and now several commercial oligo array CGH platforms
are available (Agilent, Nimblegen), we have shown here that
in-house spotting of commercially available oligonucleotide
libraries can be a cost-effective way to produce high quality,
high resolution results. There is no need for expensive and
laborious probe amplifications and as oligo libraries for new
organisms become available, these can now easily be imple-
mented for array CGH as shown by us for the mouse oligo
array CGH platform, which has already proven its value (22).
In contrast, to our knowledge only several groups have inves-
ted in producing a genome-wide mouse BAC array (15,23).
Moreover, when new libraries are designed, it is worth taking
into account that they can also be used for array CGH as is
already being done by Illumina (www.illumina.com/products/
dna/genomesets/meebo_mouse.ilmn). Special care should be
taken to design probes that are unique and show minimal
cross-hybridization. Finally, because oligonucleotide probes
are exactly defined, in contrast to PCR amplified BAC probes,
they are more suitable for use in diagnostic applications.
SUPPLEMENTARY DATA
All microarray data described in this paper are available from
the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/projects/geo/) through series accession GSE3264.
Supplementary Table 1 provides an overview of the GEO
accession numbers for the individual array experiments.
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